Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Blood (2024) 144 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2024-203781

Published: 2024

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Alessandra Ferrajoli, George Follows, Yotvat Marmor, Shogheeg Apkarian Bourjlian, Jack Roos, Naghmana Bajwa, Venkata Madhira, Kenji Nozaki, Paulo Andre P. Palhares De Miranda, Krish Patel

Blood (2023) 142 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2023-174727

Published: 2023

Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood (2023) 142 (Supplement 1): 636.

https://doi.org/10.1182/blood-2023-174750

Published: 2023

Journal Articles

Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib

George Follows, Alessandra Ferrajoli, John C. Byrd, Bob Shaw, Kenji Nozaki, Katherine Stewart, Paulo Andre P. Palhares De Miranda, Jeff P. Sharman

Blood (2023) 142 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2023-174767

Published: 2023

Journal Articles

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140774

Published: 2020

Journal Articles

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Jing Xie, Alan Yong, Catherine Waweru, PhD, Thuy Anh Sorof, Ravi K Goyal, MS, Keith L Davis, MA, George Follows, Peter Hillmen, MD PhD

Blood (2019) 134 (Supplement_1): 5885.

https://doi.org/10.1182/blood-2019-123025

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Blood (2018) 132 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2018-99-116868

Published: 2018

Journal Articles

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Pier Luigi Zinzani, MD PhD, Amita Patnaik, MD FRCP, Franck Morschhauser, MD PhD, Gilles Andre Salles, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Krimo Bouabdallah, MD, David Cunningham, MD FRCP, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Alice Benson, PhD, Peter Bonata, PhD, Isabelle Genvresse, MD, Ashok Miriyala, MD, Aruna Mehra, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin Dreyling, MD PhD

Blood (2017) 130 (Supplement 1): 4042.

https://doi.org/10.1182/blood.V130.Suppl_1.4042.4042

Published: 2017

Journal Articles

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Martin Dreyling, MD PhD, Panayiotis Panayiotidis, MD PhD, Miklos Egyed, MD PhD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Luigina Mollica, MD PhD, Arnon Nagler, MD, Muhit Ozcan, MD, Armando Santoro, MD, Tatiane Ishida, MD, Cindy Lu, PhD, Florian Hiemeyer, MSc, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4053.

https://doi.org/10.1182/blood.V130.Suppl_1.4053.4053

Published: 2017

Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Blood (2017) 130 (Supplement 1): 2777.

https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777

Published: 2017

Journal Articles

Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia

Valentin Goede, MD, Kirsten Fischer, MD, Francesc Bosch, George Follows, Henrik Frederiksen, Antonio Cuneo, Heinz Ludwig, Noelle Crompton, Joerg Maurer, Marianne Uguen, Gunter Fingerle-Rowson, Michael Hallek, MD

Blood (2015) 126 (23): 1733.

https://doi.org/10.1182/blood.V126.23.1733.1733

Published: 2015

Journal Articles

Interim PET Scan Does Not Predict Outcome in Primary Mediastinal B Cell Lymphoma Treated with R DA EPOCH

Mahesh Prahladan, MD, Nicholas F Grigoropoulos, MRCP, FRCPath, Sreetharan Munisamy, MD, Andrew Hodson, Ashley Shaw, MD, Penny Wright, FRCPath, Michael Wlliam, MD, Ramesh Bulusu, MD, Anna Sureda, MD, Charles Crawley, MD, Hk Cheow, MD, George Follows, MD, PhD

Blood (2012) 120 (21): 4846.

https://doi.org/10.1182/blood.V120.21.4846.4846

Published: 2012

Journal Articles

Rapid Response of Biallelic BRAF V600E Hairy Cell Leukaemia to Low Dose Vemurafenib

Hannah Sims, MD, David Bloxham, Hannah Creasey, MD, Elaine Bradford, MD, Hongxiang Liu, MD, Penny Wright, FRCPath, Anthony Bench, Melanie A Hopper, MD, Mars van't Veer, MD, Charles Crawley, MD, Mike Scott, George Follows, MD, PhD

Blood (2012) 120 (21): 4890.

https://doi.org/10.1182/blood.V120.21.4890.4890

Published: 2012

Journal Articles

Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells

Mathias Leddin, Chiara Perrod, Maarten Hoogenkamp, Saeed Ghani, Salam Assi, Sven Heinz, Nicola K. Wilson, George Follows, Jörg Schönheit, Lena Vockentanz, Ali M. Mosammam, Wei Chen, Daniel G. Tenen, David R. Westhead, Berthold Göttgens, Constanze Bonifer, Frank Rosenbauer

Blood (2011) 117 (10): 2827–2838.

https://doi.org/10.1182/blood-2010-08-302976

Published: 2011

Includes: Supplemental data

Journal Articles

Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors

Josette-Renée Landry, Nicolas Bonadies, Sarah Kinston, Kathy Knezevic, Nicola K. Wilson, S. Helen Oram, Mary Janes, Sandie Piltz, Michelle Hammett, Jacinta Carter, Tina Hamilton, Ian J. Donaldson, Georges Lacaud, Jonathan Frampton, George Follows, Valerie Kouskoff, Berthold Göttgens

Blood (2009) 113 (23): 5783–5792.

https://doi.org/10.1182/blood-2008-11-187757

Published: 2009

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia

Interim PET Scan Does Not Predict Outcome in Primary Mediastinal B Cell Lymphoma Treated with R DA EPOCH

Rapid Response of Biallelic BRAF V600E Hairy Cell Leukaemia to Low Dose Vemurafenib

Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells

Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only